Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 6/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.39 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538755 | 0.90 | HSD17B10 (0.46) | RIPK1NTRK1TP53CAMK2D | |
| SCHEMBL6538462 | 0.88 | HPGDS (0.52) | L3MBTL1HDAC1 | |
| SCHEMBL6539298 | 0.87 | BAZ2B (0.49) | FYNBRD4NTRK1TP53 | |
| SCHEMBL6539037 | 0.85 | NTRK1 (0.43) | NTRK1TP53 | |
| SCHEMBL6539054 | 0.85 | LMNA (0.49) | L3MBTL1GABRA5 | |
| SCHEMBL6538515 | 0.85 | ADORA2A (0.54) | CD274CAMK2D | |
| SCHEMBL6539043 | 0.84 | TP53 (0.49) | FYNNTRK1TP53 | |
| SCHEMBL6538809 | 0.84 | MEN1 (0.44) | GABRA5NTRK1TP53 | |
| SCHEMBL6538373 | 0.83 | AKT1 (0.47) | FYNNTRK1TP53 | |
| SCHEMBL6539714 | 0.81 | CYP11B1 (0.39) | FYNNTRK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067955-A1 | Pyridazinone compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067955-A1 | Pyridazinone compound and pharmaceutical use thereof | ADORA1, ADORA2A, P2RX5 | FYN 723/4885NPSR1 294/4885L3MBTL1 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.